Skip to main content

Table 2 Clinical characteristics concerning psychiatric disorders at baseline

From: Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders

 Patients (N = 144)Group AGroup Bp-value
Types of psychiatric illnesses,n(%) 101 (70.1)43 (29.9%) 
Anxiety disordersa 48 (33.3%)  
Mood disordersb 53 (36.8%)  
Psychotic disorder  43 (29.9%) 
Duration psychiatric illness, years (range)9 (6–13)8 (6.5–12.5)12 (8–15.5)0.011
Suicide attempted,n(%)5 (3.5%)2 (2%)3 (7%)0.157
Psychiatric treatment modification before DAA treatment,n(%)20 (13.9%)11 (10.9%)9 (21%)0.121
Opioid substitution treatment,n(%)12 (8.3%)2 (2%)10 (23.3%)< 0.001
Methadone11 (7.6%)1 (1%)10 (23.3%)< 0.001
Buprenorphine1 (0.7%)1 (1%)01.000
Referred alcohol consumption,n(%)5 (3.5%)4 (4%)1 (2.3%)1.000
  1. Legend:a-social phobia-posttraumatic stress disorder-panic disorder-generalized anxiety disorder;
  2. b-current major depressive episode-current manic episode-current hypomanic episode;